Latest Insider Transactions at Cvs Health Corp (CVS)
This section provides a real-time view of insider transactions for Cvs Health Corp (CVS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CVS HEALTH Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CVS HEALTH Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2024
|
Anne A. Finucane Director |
SELL
Bona fide gift
|
Direct |
2,665
-36.85%
|
$149,240
$56.86 P/Share
|
|
Nov 30
2024
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
86
-1.01%
|
$5,074
$59.85 P/Share
|
|
Nov 30
2024
|
Heidi B Capozzi EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
83,542
+50.0%
|
$4,928,978
$59.85 P/Share
|
|
Nov 30
2024
|
Roger N Farah Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,125
+50.0%
|
$2,957,375
$59.85 P/Share
|
|
Nov 30
2024
|
Tilak Mandadi EVP, Chief DDAT Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,125
+33.45%
|
$2,957,375
$59.85 P/Share
|
|
Nov 21
2024
|
Guy P Sansone Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,200
+20.83%
|
$125,400
$57.1 P/Share
|
|
Nov 21
2024
|
Douglas H. Shulman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,200
+50.0%
|
$125,400
$57.1 P/Share
|
|
Nov 21
2024
|
Leslie V Norwalk Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,200
+50.0%
|
$125,400
$57.1 P/Share
|
|
Nov 21
2024
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,200
+32.77%
|
$125,400
$57.1 P/Share
|
|
Nov 21
2024
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,331
+6.39%
|
$132,867
$57.1 P/Share
|
|
Nov 21
2024
|
J Scott Kirby Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,933
+25.51%
|
$167,181
$57.1 P/Share
|
|
Nov 21
2024
|
Michael F Mahoney Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,200
+26.19%
|
$125,400
$57.1 P/Share
|
|
Nov 21
2024
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,364
+6.02%
|
$134,748
$57.1 P/Share
|
|
Nov 21
2024
|
Jeffrey R. Balser Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,375
+19.75%
|
$135,375
$57.1 P/Share
|
|
Nov 21
2024
|
C David Brown Ii Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,331
+1.85%
|
$132,867
$57.1 P/Share
|
|
Aug 31
2024
|
Tilak Mandadi EVP, Chief DDAT Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,097
-24.48%
|
$746,529
$57.24 P/Share
|
|
May 16
2024
|
J Scott Kirby Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,912
+34.08%
|
$165,984
$57.52 P/Share
|
|
May 16
2024
|
Michael F Mahoney Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,184
+35.31%
|
$124,488
$57.52 P/Share
|
|
May 16
2024
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,314
+50.0%
|
$131,898
$57.52 P/Share
|
|
May 16
2024
|
C David Brown Ii Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,314
+1.87%
|
$131,898
$57.52 P/Share
|
|
May 16
2024
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,314
+6.78%
|
$131,898
$57.52 P/Share
|
|
May 16
2024
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,347
+6.37%
|
$133,779
$57.52 P/Share
|
|
May 16
2024
|
Jeffrey R. Balser Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,184
+23.08%
|
$124,488
$57.52 P/Share
|
|
May 02
2024
|
Michael F Mahoney Director |
BUY
Open market or private purchase
|
Direct |
9,181
+49.53%
|
$495,774
$54.49 P/Share
|
|
May 02
2024
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
1,000
+4.42%
|
$53,000
$53.88 P/Share
|
|
Apr 01
2024
|
J. David Joyner President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
28,280
+39.0%
|
-
|
|
Apr 01
2024
|
Laurie P. Havanec EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,426
+50.0%
|
$744,654
$79.56 P/Share
|
|
Apr 01
2024
|
Laurie P. Havanec EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,630
-16.89%
|
$602,770
$79.56 P/Share
|
|
Apr 01
2024
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,913
+22.61%
|
$546,127
$79.56 P/Share
|
|
Apr 01
2024
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,298
-8.88%
|
$181,542
$79.56 P/Share
|
|
Apr 01
2024
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,683
+41.42%
|
$843,957
$79.56 P/Share
|
|
Apr 01
2024
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,004
-14.03%
|
$237,316
$79.56 P/Share
|
|
Apr 01
2024
|
Samrat S. Khichi EVP, CPO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
12,569
+22.03%
|
-
|
|
Apr 01
2024
|
Brian A Kane EVP/President, Aetna |
BUY
Grant, award, or other acquisition
|
Direct |
12,569
+50.0%
|
-
|
|
Apr 01
2024
|
Tilak Mandadi EVP, Chief DDAT Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,339
+16.46%
|
-
|
|
Apr 01
2024
|
Prem S Shah EVP and Group President |
BUY
Grant, award, or other acquisition
|
Direct |
15,082
+28.93%
|
-
|
|
Apr 01
2024
|
Prem S Shah EVP and Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
7,892
-8.2%
|
$623,468
$79.56 P/Share
|
|
Apr 01
2024
|
Thomas F. Cowhey EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,082
+23.91%
|
-
|
|
Apr 01
2024
|
Thomas F. Cowhey EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,719
-4.6%
|
$135,801
$79.56 P/Share
|
|
Apr 01
2024
|
Karen S Lynch President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
61,953
-45.34%
|
$4,894,287
$79.56 P/Share
|
|
Apr 01
2024
|
Karen S Lynch President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
45,248
+50.0%
|
$3,574,592
$79.56 P/Share
|
|
Feb 28
2024
|
Thomas F. Cowhey EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,641
-16.46%
|
$423,075
$75.19 P/Share
|
|
Feb 28
2024
|
J. David Joyner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,970
-4.62%
|
$147,750
$75.19 P/Share
|
|
Feb 28
2024
|
Samrat S. Khichi EVP, CPO and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
6,210
-38.91%
|
$465,750
$75.19 P/Share
|
|
Feb 26
2024
|
Prem S Shah EVP and Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
261
-0.6%
|
$19,836
$76.43 P/Share
|
|
Feb 26
2024
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
355
-3.66%
|
$26,980
$76.43 P/Share
|
|
Feb 26
2024
|
Laurie P. Havanec EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,698
-12.91%
|
$509,048
$76.43 P/Share
|
|
Feb 16
2024
|
Prem S Shah EVP and Group President |
SELL
Open market or private sale
|
Direct |
29,473
-42.57%
|
$2,239,948
$76.95 P/Share
|
|
Feb 12
2024
|
Laurie P. Havanec EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,817
+31.13%
|
-
|
|
Feb 12
2024
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,926
+18.22%
|
-
|